Gene expression data from 4T1 irradiated tumors treated with TGFbeta blockade
Resources
1 resource available
-
Gene expression data from 4T1 irradiated tumors treated with TGFbeta blockade
HTML
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| accrualPeriodicity | irregular |
| bureauCode |
[
"026:00"
]
|
| contactPoint |
{
"fn": "GeneLab Outreach",
"@type": "vcard:Contact",
"hasEmail": "mailto:genelab-outreach@lists.nasa.gov"
}
|
| description | Accumulating data support the concept that ionizing radiation therapy (RT) has the potential to convert the tumor into an in situ individualized vaccine; however this potential is rarely realized by RT alone. Transforming growth factor xce xb2 (TGF xce xb2) is an immunosuppressive cytokine that is activated by RT and inhibits the antigen-presenting function of dendritic cells and the differentiation of effector CD8+ T cells. Here we tested the hypothesis that TGF xce xb2 hinders the ability of RT to promote anti-tumor immunity. Development of tumor-specific immunity was examined in a pre-clinical model of metastatic breast cancer. Mice bearing established 4T1 mouse mammary carcinoma treated with pan-isoform specific TGF xce xb2 neutralizing antibody 1D11 showed significantly improved control of the irradiated tumor and non-irradiated metastases but no effect in the absence of RT. Notably whole tumor transcriptional analysis demonstrated the selective upregulation of genes associated with immune-mediated rejection only in tumors of mice treated with RT+TGF xce xb2 blockade. Mice treated with RT+TGF xce xb2 blockade exhibited cross-priming of CD8+ T cells producing IFN xce xb3 in response to three tumor-specific antigens in tumor-draining lymph nodes which was not evident for single modality treatment. Analysis of the immune infiltrate in mouse tumors showed a significant increase in CD4+ and CD8+ T cells only in mice treated with the combination of RT+TGF xce xb2 blockade. Depletion of CD4+ or CD8+ T cells abrogated the therapeutic benefit of RT+TGF xce xb2 blockade. These data identify TGF xce xb2 as a master inhibitor of the ability of RT to generate an in situ tumor vaccine which supports testing inhibition of TGF xce xb2 during radiotherapy to promote therapeutically effective anti-tumor immunity. We used genome-wide microarray to depict main biological processes responsibles for the therapeutic benefit of the combination ofTGF-beta blockade and local radiotherapy. To gain a more comprehensice protrait of the effects of RT and TGFbeta blockade on gene expressionin tumors we collected 4T1 tumors 4 days after completion of RT. Three tumors from each group were then subjected to RNA extraction and hybridization on affymetrix array. |
| distribution |
[
{
"@type": "dcat:Distribution",
"title": "Gene expression data from 4T1 irradiated tumors treated with TGFbeta blockade",
"format": "HTML",
"mediaType": "text/html",
"description": "GeneLab Study Page",
"downloadURL": "https://genelab-data.ndc.nasa.gov/genelab/accession/GLDS-160"
}
]
|
| identifier | nasa_genelab_GLDS-160_vz54-rnde |
| issued | 2021-05-21 |
| keyword |
[
"array-scanning-protocol",
"data-transformation",
"genelab-microarray-data-processing-protocol",
"growth-protocol",
"hybridization-protocol",
"ionizing-radiation",
"labelling-protocol",
"normalization-data-transformation-protocol",
"nucleic-acid-extraction-protocol",
"p-gse61208-1",
"p-gse61208-2",
"p-gse61208-3",
"p-gse61208-4",
"p-gse61208-5",
"p-gse61208-6",
"p-gse61208-7",
"sample-treatment-protocol",
"treatment"
]
|
| landingPage | https://data.nasa.gov/dataset/gene-expression-data-from-4t1-irradiated-tumors-treated-with-tgfbeta-blockade |
| license | http://www.usa.gov/publicdomain/label/1.0/ |
| modified | 2025-04-23 |
| programCode |
[
"026:005"
]
|
| publisher |
{
"name": "National Aeronautics and Space Administration",
"@type": "org:Organization"
}
|
| theme |
[
"Earth Science"
]
|
| title | Gene expression data from 4T1 irradiated tumors treated with TGFbeta blockade |